Sanofi (SAN) PT Set at €93.00 by Deutsche Bank
Sanofi (EPA:SAN) has been given a €93.00 ($110.71) price objective by equities researchers at Deutsche Bank in a research report issued on Friday. The firm presently has a “buy” rating on the stock. Deutsche Bank’s price objective suggests a potential upside of 27.62% from the stock’s current price.
Several other equities analysts have also issued reports on the company. Jefferies Group set a €80.00 ($95.24) price target on Sanofi and gave the stock a “neutral” rating in a research report on Tuesday. S&P Global set a €83.00 ($98.81) price target on Sanofi and gave the stock a “neutral” rating in a research report on Friday, November 3rd. Goldman Sachs Group set a €82.00 ($97.62) price target on Sanofi and gave the stock a “neutral” rating in a research report on Friday, November 3rd. set a €78.00 ($92.86) price target on Sanofi and gave the stock a “neutral” rating in a research report on Friday, November 3rd. Finally, Berenberg Bank set a €97.00 ($115.48) price target on Sanofi and gave the stock a “neutral” rating in a research report on Thursday, November 2nd. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating to the company’s stock. Sanofi has a consensus rating of “Hold” and a consensus price target of €86.88 ($103.42).
Sanofi (SAN) opened at €72.87 ($86.75) on Friday. Sanofi has a 1 year low of €71.06 ($84.60) and a 1 year high of €92.97 ($110.68). The stock has a market capitalization of $92,040.00 and a P/E ratio of 20.19.
COPYRIGHT VIOLATION NOTICE: This article was reported by Daily Political and is owned by of Daily Political. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/01/19/sanofi-san-pt-set-at-93-00-by-deutsche-bank.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.